Use your antibodies-online credentials, if available.
Keine Produkte auf Ihrer Vergleichsliste.
Ihr Warenkorb ist leer.
Alle Spezies anzeigen
Weitere Synonyme anzeigen
Wählen Sie die Spezies und Applikation aus
anti-Human HER2 Antikörper:
anti-Mouse (Murine) HER2 Antikörper:
anti-Rat (Rattus) HER2 Antikörper:
Sie gelangen zu unserer vorgefilterten Suche.
Human Monoclonal HER2 Primary Antibody für IHC (p) - ABIN1687346
Park, Kang, Kim: Does background parenchymal enhancement on MRI affect the rate of positive resection margin in breast cancer patients? in The British journal of radiology 2015
Show all 56 Pubmed References
Human Monoclonal HER2 Primary Antibody für IHC (p) - ABIN1688892
Savci-Heijink, Halfwerk, Hooijer, Horlings, Wesseling, van de Vijver: Retrospective analysis of metastatic behaviour of breast cancer subtypes. in Breast cancer research and treatment 2015
Show all 50 Pubmed References
Human Monoclonal HER2 Primary Antibody für IHC (fro), IHC (p) - ABIN967459
Carraway, Cantley: A neu acquaintance for erbB3 and erbB4: a role for receptor heterodimerization in growth signaling. in Cell 1994
Show all 9 Pubmed References
Human Monoclonal HER2 Primary Antibody für IHC (f), IHC (fro) - ABIN2688859
Rubin, Finstad, Wong, Almadrones, Plante, Lloyd: Prognostic significance of HER-2/neu expression in advanced epithelial ovarian cancer: a multivariate analysis. in American journal of obstetrics and gynecology 1993
Show all 7 Pubmed References
Human Polyclonal HER2 Primary Antibody für IHC - ABIN966279
Dittadi, Gion: More about: prognostic importance of low c-erbB2 expression in breast tumors. in Journal of the National Cancer Institute 2000
Show all 6 Pubmed References
Human Monoclonal HER2 Primary Antibody für IF, IP - ABIN967786
Dillon, Creer, Kerr, Kümin, Dickson: Basolateral targeting of ERBB2 is dependent on a novel bipartite juxtamembrane sorting signal but independent of the C-terminal ERBIN-binding domain. in Molecular and cellular biology 2002
Show all 5 Pubmed References
Human Monoclonal HER2 Primary Antibody für IF, IP - ABIN967787
Graus-Porta, Beerli, Hynes: Single-chain antibody-mediated intracellular retention of ErbB-2 impairs Neu differentiation factor and epidermal growth factor signaling. in Molecular and cellular biology 1995
Show all 5 Pubmed References
Human Polyclonal HER2 Primary Antibody für IHC - ABIN966277
Marone, Hess, Dankort, Muller, Hynes, Badache: Memo mediates ErbB2-driven cell motility. in Nature cell biology 2004
Show all 5 Pubmed References
Mouse (Murine) Polyclonal HER2 Primary Antibody für DB - ABIN1881306
Cabodi, Tinnirello, Bisaro, Tornillo, del Pilar Camacho-Leal, Forni, Cojoca, Iezzi, Amici, Montani, Eva, Di Stefano, Muthuswamy, Tarone, Turco, Defilippi: p130Cas is an essential transducer element in ErbB2 transformation. in FASEB journal : official publication of the Federation of American Societies for Experimental Biology 2010
Show all 5 Pubmed References
Human Polyclonal HER2 Primary Antibody für DB, WB - ABIN1881408
Brandt, Mikesch, Simon, Rötger, Kemming, Schier, Sauter, Bürger: Selective expression of a splice variant of decay-accelerating factor in c-erbB-2-positive mammary carcinoma cells showing increased transendothelial invasiveness. in Biochemical and biophysical research communications 2005
Show all 5 Pubmed References
the antibody-sialidase conjugate desialylated tumor cells in a HER2-dependent manner, reduced binding by natural killer (NK) cell inhibitory sialic acid-binding Ig-like lectin (Siglec) receptors, and enhanced binding to the NK-activating receptor natural killer group 2D (NKG2D (zeige KLRK1 Antikörper)).
High HER2 expression is associated with gastric cancer.
In the CNIO-BR-003/GEICAM/2010-10 study, we were able to show a predictive role of 18F-FMISO-PET in HER2-negative early breast cancer treated with nintedanib, detecting the patients that do not experience benefit from it based on baseline tumor oxygenation levels
High HER2 expression is associated with non-small cell lung cancer.
Although new treatments have been approved for patients with ER+/HER2- advanced or MBC (zeige DOCK2 Antikörper) in the past decade, neither survival nor QoL appear to have improved significantly.
HER2 reduces the radiosensitivity of breast cancer by activating Fak (zeige PTK2 Antikörper) in vitro and in vivo.
HER2 insertion could define a distinct subset of NSCLC, which had a higher prevalence among females, nonsmokers, and adenocarcinoma. HER2 should be in the clinical genotyping of lung cancer, so patients may benefit from HER2-targeted therapy.
Data show that epidermal growth factor receptor (zeige EGFR Antikörper) 2 (HER2) single-point substations such as D769H and D769Y as well as the gatekeeper mutation T798 M were predicted to cause strong resistance for an array of tyrosine kinase (zeige TXK Antikörper) inhibitors (TKIs) by reshaping the geometric feature and physiochemical property of the active site.
Anti-HER-2 and hormonal therapy, except tamoxifen, have been underutilized in Korean male breast cancer patients compared to female breast cancer patients.
Data show that inhibition of S100 calcium binding protein P (S100P (zeige S100P Antikörper)) results in reversing trastuzumab resistance (TzR) in proto-oncogene (zeige RAB1A Antikörper) protein HER-2 (HER2)-driven breast cancers.
YAP (zeige YAP1 Antikörper) accumulated in nuclei of mammary glands in ErbB2/EGFR (zeige EGFR Antikörper)-transgenic mice, suggesting that EGFR (zeige EGFR Antikörper) signaling affects YAP (zeige YAP1 Antikörper) in vivo similar to cell culture. ErbB2/EGFR (zeige EGFR Antikörper)-transgenic mice develop mammary tumors in 7-8 months, but surprisingly, MaSCs from these mice did not form tumors when transplanted into host mice.
Results indicate the importance of the LDL receptor (LDLR (zeige LDLR Antikörper)) in the growth of triple-negative and HER2-overexpressing breast cancers in the setting of elevated circulating LDL cholesterol (LDL-C).
immunocompetent mouse models of HER2/ErbB2-driven breast cancer, CD73 expression by tumor cells and host cells significantly suppressed immune-mediated responses mediated by anti-ErbB2 mAb.
We further demonstrate that loss of one allele of PTEN (zeige PTEN Antikörper) is sufficient to shift isoform dependency from p110alpha (zeige PIK3CA Antikörper) to p110beta in vivo. These results provide insight into the molecular mechanism by which ErbB2-positive breast cancer escapes p110alpha (zeige PIK3CA Antikörper) inhibition.
sought to further echocardiographically characterize the ErbB2(tg) mouse line as a model of hypertrophic obstructive cardiomyopathy
investigations revealed that NUMB (zeige NUMB Antikörper) and NUMBL (zeige NUMBL Antikörper) interacted with small GTPase (zeige RACGAP1 Antikörper) Rab7 (zeige RAB7A Antikörper) to transition ERBB2 from early to late endosome for degradation.
Combined targeting of TGF-beta (zeige TGFB1 Antikörper), EGFR (zeige EGFR Antikörper) and HER2 signaling suppresses lymphangiogenesis and metastasis in a pancreatic ductal adenocarcinoma model.
The conjugation of benzylguanine-modified auristatin F to EGFR (zeige EGFR Antikörper)-specific 425(scFv)-SNAP and HER2-specific alphaHER2(scFv)-SNAP resulted in two potent recombinant antibody-drug conjugates that specifically killed breast cancer cell lines by inducing apoptosis when applied at nanomolar concentrations.
ErbB2 is required for neonatal cardiomyocyte proliferation. ErbB2 conditional knockout heart exhibited an upregulation of negative cell cycle regulators.
Despite previous evidence suggesting that ErbB (zeige EGFR Antikörper) receptors can bind and activate IRSs, our findings indicate that ErbB2 does not cooperate with the IRS (zeige IARS Antikörper) pathway in mouse breast cancer model.
Newly synthesized N-cadherin (zeige CDH2 Antikörper) molecules move from the lateral to the basal surface of cardiomyocytes during trabeculation. This localization requires Erbb2 signaling.
these results suggest that Nrg1 (zeige NRG1 Antikörper) is not the primary effector of trabeculation and/or that other EGF (zeige EGF Antikörper)-like ligand(s) activates the ErbB2/ErbB4 (zeige ERBB4 Antikörper) pathway, either through functioning as the primary ligand or acting in a redundant manner. Overall, our work provides an example of cross-species differences in EGF (zeige EGF Antikörper) family member requirements for an evolutionary conserved process.
Embryos homozygous for a GBT insertion within neuregulin 2a (nrg2a) revealed a novel requirement for a Neuregulin 2a (Nrg2a)-ErbB2/3-AKT (zeige AKT1 Antikörper) signaling pathway governing the organization of a subset of epidermal cells during median fin fold morphogenesis.
A direct link was found between Erbb2 activity and remodeling of myofibrils.
Study shows that, in addition to its role in cardiomyocyte proliferation, ErbB2 is also required for regulating cardiomyocyte migration (delamination) to initiate cardiac trabeculation.
erbb3 (zeige ERBB3 Antikörper) and erbb2 are essential for schwann cell migration and myelination in zebrafish.
NRG1 (zeige NRG1 Antikörper) and PI3K functionally interact with ErbB2 and ErbB3 (zeige ERBB3 Antikörper) during regeneration
Results indicated that most periocular squamous cell carcinomas of horses expressed epidermal growth factor receptor (EGFR (zeige EGFR Antikörper)) and human epidermal growth factor receptor (zeige EGFR Antikörper) 2 (HER2).[HER2]
Widespread expression of ErbB2 receptor mRNAs was found throughout the telencephalon of juvenile and adult monkeys with in situ hybridization, with higher levels in grey matter compared to white matter.
We have isolated the cDNA encoding the rhesus monkey homolog of human Her2/neu (RhErbB2) to construct DNA plasmids and adenoviral vectors for the development of a cancer vaccine against this protein.
This gene encodes a member of the epidermal growth factor (EGF) receptor family of receptor tyrosine kinases. This protein has no ligand binding domain of its own and therefore cannot bind growth factors. However, it does bind tightly to other ligand-bound EGF receptor family members to form a heterodimer, stabilizing ligand binding and enhancing kinase-mediated activation of downstream signalling pathways, such as those involving mitogen-activated protein kinase and phosphatidylinositol-3 kinase. Allelic variations at amino acid positions 654 and 655 of isoform a (positions 624 and 625 of isoform b) have been reported, with the most common allele, Ile654/Ile655, shown here. Amplification and/or overexpression of this gene has been reported in numerous cancers, including breast and ovarian tumors. Alternative splicing results in several additional transcript variants, some encoding different isoforms and others that have not been fully characterized.
c-erb B2/neu protein
, metastatic lymph node gene 19 protein
, neuro/glioblastoma derived oncogene homolog
, neuroblastoma/glioblastoma derived oncogene homolog
, proto-oncogene Neu
, proto-oncogene c-ErbB-2
, receptor tyrosine-protein kinase erbB-2
, tyrosine kinase-type cell surface receptor HER2
, v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog
, Neu oncogene
, avian erythroblastosis oncogene B 2
, proto-oncogene NEU
, Avian erythroblastosis viral (v-erb-B2) oncogene homologue 2 (neuro/glioblastoma derived oncogene homolog)
, NEU proto-oncogene
, epidermal growth factor receptor-related protein
, v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2
, epidermal growth factor receptor type 2